WB | 咨询技术 | Human,Mouse,Rat |
IF | 咨询技术 | Human,Mouse,Rat |
IHC | 咨询技术 | Human,Mouse,Rat |
ICC | 技术咨询 | Human,Mouse,Rat |
FCM | 咨询技术 | Human,Mouse,Rat |
Elisa | 咨询技术 | Human,Mouse,Rat |
Host/Isotype | Mouse IgG1 |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | Purified recombinant fragment of human IL3 |
Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4篇关于IL3抗体的代表性文献概览(内容基于学术研究背景整理,具体文献信息可能需要进一步验证):
---
1. **文献名称**:*Targeting IL-3 receptors in AML: A novel therapeutic strategy*
**作者**:Smith A, et al.
**摘要**:该研究探讨了抗IL-3受体(CD123)抗体在急性髓系白血病(AML)中的治疗潜力。实验表明,阻断IL-3信号通路可抑制白血病干细胞增殖并促进凋亡,为AML靶向治疗提供了新方向。
2. **文献名称**:*Neutralization of IL-3 ameliorates allergic airway inflammation in murine models*
**作者**:Chen L, et al.
**摘要**:通过动物实验证明,抗IL-3中和抗体可减少嗜酸性粒细胞和肥大细胞的活化,显著缓解哮喘模型中的气道高反应性和炎症反应,提示IL-3抗体在过敏性疾病中的治疗价值。
3. **文献名称**:*IL-3 receptor signaling and its role in hematopoietic cell survival*
**作者**:Miyajima A, et al.
**摘要**:该基础研究阐明了IL-3受体介导的JAK-STAT信号通路对造血细胞存活和分化的调控机制,为开发靶向IL-3/受体抗体的药物提供了理论依据。
4. **文献名称**:*Engineered anti-IL-3 antibodies enhance CAR-T cell efficacy against solid tumors*
**作者**:Wang Y, et al.
**摘要**:研究团队设计了一种新型抗IL-3抗体片段,将其与CAR-T细胞联合应用,可有效抑制肿瘤微环境中IL-3介导的免疫抑制,显著提升实体瘤治疗效果。
---
**注**:以上文献信息为示例性质,实际引用时需根据具体论文核实作者、标题及内容。如需精准文献,建议通过PubMed或Web of Science以“IL-3 antibody”或“anti-IL3 therapy”等关键词检索。
Interleukin-3 (IL-3) is a cytokine primarily involved in hematopoiesis, immune regulation, and inflammation. It is produced by activated T cells, mast cells, and stromal cells, and functions by binding to the IL-3 receptor (IL-3R), a heterodimer composed of α (CD123) and β (CD131) subunits. This interaction activates signaling pathways such as JAK-STAT, MAPK, and PI3K, promoting the survival, proliferation, and differentiation of hematopoietic stem cells, particularly myeloid lineages like mast cells, basophils, and megakaryocytes. Dysregulation of IL-3 signaling is implicated in allergic disorders, autoimmune diseases, and hematologic malignancies, including acute myeloid leukemia (AML).
IL-3 antibodies are tools or therapeutics designed to target IL-3 or its receptor. Research-grade antibodies are widely used in immunoassays (e.g., ELISA, flow cytometry) to quantify IL-3 levels or map its expression in physiological and pathological contexts. Therapeutic monoclonal antibodies (mAbs) or antibody-drug conjugates (ADCs) against CD123 (IL-3Rα) have gained attention for treating CD123-positive cancers, aiming to block IL-3-mediated survival signals or deliver cytotoxic payloads to malignant cells. Challenges include managing on-target off-tumor effects due to CD123’s expression on healthy hematopoietic cells. Recent advancements include bispecific antibodies and CAR-T therapies targeting IL-3R, though clinical efficacy and safety remain under investigation. Overall, IL-3 antibodies bridge basic research and translational medicine, offering insights into immune regulation and novel cancer treatment strategies.
×